Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (4): 318-321.doi: 10.3969/j.issn.1000-6621.2021.04.004
• Special Articles • Previous Articles Next Articles
Received:
2021-01-13
Online:
2021-04-10
Published:
2021-04-09
Contact:
DENG Guo-fang
E-mail:jxxk1035@yeah.net
DENG Guo-fang. Interpretation of Expert consensus on treatment and management of tuberculosis-diabetes mellitus comorbidity[J]. Chinese Journal of Antituberculosis, 2021, 43(4): 318-321. doi: 10.3969/j.issn.1000-6621.2021.04.004
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.04.004
临床类别 | 血糖控制目标 |
---|---|
结核病治疗期间[ | |
年龄较轻、病程较短、预期寿命较长、无并发症、未并发心血管疾病 | HbA1c<7.0%,空腹<7.0mmol/L,非空腹<10.0mmol/L |
并发心脑血管疾病、心脑血管疾病高风险、高龄、结核病病情严重 | HbA1c<8.0%,空腹7.8~10.0mmol/L,非空腹 7.8~13.9mmol/L |
非结核病治疗期间[ | |
年龄较轻、病程较短、预期寿命较长、无并发症、未并发心血管疾病 | HbA1c<6.5%,空腹4.4~6.1mmol/L,非空腹 6.1~7.8mmol/L |
大多数非妊娠成年2型糖尿病患者 | HbA1c<7.0%,空腹 4.4~7.0mmol/L,非空腹<10.0mmol/L |
高龄、低血糖发生风险较高且无法耐受低血糖、存在多器官功能不全、预期生存期低于5年、需重症监护 | HbA1c<8.0%,空腹7.8~10.0mmol/L,非空腹 7.8~13.9mmol/L |
[1] |
Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019,7(4):e448-e460. doi: 10.1016/S2214-109X(18)30487-X.
doi: 10.1016/S2214-109X(18)30487-X URL pmid: 30819531 |
[2] | 国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 等. 结核病与糖尿病共病的治疗管理专家共识. 中国防痨杂志, 2021,43(1):12-22. doi: 10.3969/j.issn.1000-6621.2021.01.004. |
[3] |
Kernick D, Chew-Graham CA, O’Flynn N. Clinical assessment and management of multimorbidity: NICE guideline. Br J Gen Pract, 2017,67(658):235-236. doi: 10.3399/bjgp17X690857.
doi: 10.3399/bjgp17X690857 URL pmid: 28450343 |
[4] | 颜俊娴, 路云. 英国共病管理政策对我国的启示. 现代商贸工业, 2018,6:66-68. doi: 10.19311/j.cnki.1672-3198.2018.06.028. |
[5] |
Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med, 2011,9:81. doi: 10.1186/1741-7015-9-81.
doi: 10.1186/1741-7015-9-81 URL pmid: 21722362 |
[6] | Lin Y, Harries AD, Kumar AM, et al. Management of diabetes mellitus-tuberculosis: a guide to the essential practice. Paris: International Union Against Tuberculosis and Lung Disease, 2019. |
[7] |
Harries AD, Kumar AM, Satyanarayana S, et al. Diabetes mellitus and tuberculosis: programmatic management issues. Int J Tuberc Lung Dis, 2015,19(8):879-886. doi: 10.5588/ijtld.15.0069.
doi: 10.5588/ijtld.15.0069 URL pmid: 26162352 |
[8] |
Lin Y, Yuan Y, Zhao X, et al. The change in blood glucose levels in tuberculosis patients before and during anti-tuberculosis treatment in China. Glob Health Action, 2017,10(1):1289737.doi: 10.1080/16549716.2017.1289737.
doi: 10.1080/16549716.2017.1289737 URL pmid: 28470109 |
[9] |
Lin Y, Li L, Mi F, et al. Screening patients with diabetes mellitus for tuberculosis in China. Trop Med Int Health, 2012,17(10):1302-1308. doi: 10.1111/j.1365-3156.2012.03069.x.
doi: 10.1111/j.1365-3156.2012.03069.x URL |
[10] |
Lin Y, Innes A, Xu L, et al. Screening of patients with diabetes mellitus for tuberculosis in community health settings in China. Trop Med Int Health, 2015,20(8):1073-1080. doi: 10.1111/tmi.12519.
doi: 10.1111/tmi.12519 URL pmid: 25877338 |
[11] |
Yoon YS, Jung JW, Jeon EJ, et al. The effect of diabetes control status on treatment response in pulmonary tuberculosis: a prospective study. Thorax, 2017,72(3):263-270. doi: 10.1136/thoraxjnl-2015-207686.
doi: 10.1136/thoraxjnl-2015-207686 URL pmid: 27553224 |
[12] | 中国医师协会内分泌代谢科医师分会, 中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识. 中华内分泌代谢杂志, 2017,33(1):1-10. doi: 10.3760.j.issn.1000-6699.2017.01.001. |
[13] |
Lin KH, Luo CW, Chen SP, et al. α-Glucosidase Inhibitor Can Effectively Inhibit the Risk of Tuberculosis in Patients with Diabetes: A Nested Case-Control Study. Biomed Res Int, 2020,2020:8085106. doi: 10.1155/2020/8085106.
doi: 10.1155/2020/8085106 URL pmid: 32509871 |
[14] |
Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months. Chest, 2015,147(2):520-528. doi: 10.1378/chest.14-0918.
doi: 10.1378/chest.14-0918 URL pmid: 25255302 |
[15] | Chang JT, Dou HY, Yen CL, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc, 2011,110(6):372-381. doi: 10.1016/S0929-6646(11)60055-7. |
[16] | Atif M, Sulaiman SA, Shafie AA, et al. Duration of treatment in pulmonary tuberculosis: are international guidelines on the management of tuberculosis missing something. Public Health, 2015,129(6):777782. doi: 10.1016/j.puhe.2015.04.010. |
[17] |
Wu Z, Guo J, Huang Y, et al. Diabetes mellitus in patients with pulmonary tuberculosis in an aging population in Shanghai, China: Prevalence, clinical characteristics and outcomes. J Diabetes Complications, 2016,30(2):237-241. doi: 10.1016/j.jdiacomp.2015.11.014.
doi: 10.1016/j.jdiacomp.2015.11.014 URL pmid: 26684166 |
[1] | MA Yan*, GAO Wei-wei. Pay attention to the reasonable treatment of retreatment tuberculosis:today is not what it used to be [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 313-317. |
[2] | SHU Wei, GE Qi-ping, HUANG Xue-rui, MA Li-ping, JI Bin-ying, CHEN Yu-hui, CHEN Xiao-you, JIANG Guang-lu, XIE Li, LI Bo, CHEN Sheng-yu, CHEN Sen-lin, YAN Jun-ping, SHI Lian, CHEN Ling, LI You-lun, XI Xiu-e, LIU Qian-ying, YAN Xing-lu, WANG Fei, WANG Fu-rong, WU Xiang, ZHANG Peng, LENG Xue-yan, CAO Wen-li, ZHANG Hai-qing, CUI Hong-zhe, YANG Cheng-qing, WU Chao, LI Juan, LI Hua, SUN Yu-xian, ZHANG Li-jie, XIE Shi-heng, NING Yu-jia, TIAN Xi-zhong, DU Jian, LI Liang, GAO Wei-wei. Analysis of treatment outcomes of retreated pulmonary tuberculosis patients with isoniazid-resistance and rifampin-resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 322-327. |
[3] | GE Qi-ping*, DU Jian, SHU Wei, MA Yan, MA Li-ping, ZHAO Cai-yan, CHEN Yu-hui, ZHANG Li-jie, HUANG Xue-rui, HAN Xi-qin, CHEN Sheng-yu, WANG Fei, LI Bo, CAO Wen-li, LIU Qian-ying, CHEN Dong-jin, SHI Lian, WANG Xin, LI You-lun, YANG Shang-peng, PENG Zhang-li, WU Chao, OUYANG Bing, WANG Fu-rong, LI Po, WU Xiang, XI Xiu-e, LENG Xue-yan, ZHANG Hai-qing, LI Hua, LI Juan, YANG Cheng-qing, ZHANG Peng, CUI Hong-zhe, XIE Li, LIU Yu-hong, LI Liang, GAO Wei-wei. Treatment effect analysis of the optimized regimen for re-treated drug-susceptible pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 328-334. |
[4] | ZHANG Li-jie*, HAN Xi-qin, WANG Jing-ping, CHEN Yu-hui, CHEN Sheng-yu, CHEN Ling, LI Bo, LIN Ming-gui, LI You-lun, SHI Lian, XI Xiu-e, MA Li-ping, WANG Xin, WANG Fei, ZHAO Cai-yan, WANG Fu-rong, CHEN Sen-lin, WU Xiang, LI Po, ZHANG Peng, LENG Xue-yan, ZHANG Hai-qing, CAO Wen-li, SHU Wei, SUN Yu-xian, XIE Shi-heng, TIAN Xi-zhong, HUANG Xue-rui, DU Jian, GAO Wei-wei. The relationship between bacterial load and treatment failure and recurrence of sputum positive retreatment pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 335-340. |
[5] | LIANG Rui-yun, FANG Wei-jun, REN Hui-li, LI Hui-ru, ZHANG Hui, LI Cheng-cheng. Analysis of CT features of drug-resistant pulmonary tuberculosis with cavity [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 341-345. |
[6] | YU Shan, LI Zhi-ming, XU Chun-xia, WANG Tao. Analysis of risk factors associated with false negative results of interferon-gamma release assays on peripheral blood from tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 346-351. |
[7] | LIU Ting*, WANG Liang, YANG Mei. The study on the anti-tuberculosis activity of polymorphonuclear cell from peripheral blood of patients with multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 352-356. |
[8] | ZHANG Chen-chen*, TAN Wei-guo, GUO Hui-xin, HUANG Xin-chun, CHEN Yan-mei, WEI Wen-jing. The effect of Mycobacterium tuberculosis infection on sputum flora structure [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 357-363. |
[9] | BAI Hua, GUO Jing-wei, HU Pei-lei, YI Song-lin, WEN Jia, LIU Feng-ping, TAN Yun-hong, BAI Li-qiong. Analysis of drug resistance surveillance results of Mycobacterium tuberculosis in Hu’nan Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 364-369. |
[10] | WANG Huan*, SHEN Xin, CHEN Jing, XIA Zhen, XU Biao, YUAN Zheng-an. Analysis of the epidemiological characteristics of pulmonary tuberculosis among migrants in Shanghai from 2008 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 370-377. |
[11] | MA Zhi-tao, WANG Na, LYU Yang, HU Wei-hong, CHEN Chang, HE Fan, SHEN Xin, LIU Xiao-feng. The research on psychological status of pulmonary tuberculosis patients and influencing factors in Baoshan District, Shanghai [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 378-384. |
[12] | LI Zhi-hong, GU Kan-kai, YAO Jing, ZHANG Huai-qing, HAN Zhi-ying, SHEN Xin, CHEN Jing, SHEN Bing. Analysis of screening of close contacts of a tuberculosis patient in a kindergarten in downtown Shanghai [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 385-390. |
[13] | Maiweilanjiang· Abulimiti, Diermulati· Tusun, LIU Zhen-jiang, Xirizhati· Mamuti, LI Guan-zhen, OU Xi-chao. Analysis on the therapeutic effect and influencing factors of initial treated smear-positive pulmonary tuberculosis patients in Kashgar Prefecture from 2016 to 2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 391-397. |
[14] | ZHOU Shuang, CHEN Nan, ZHU Kun, JIANG Hui, YANG Lei, DU Jian. Investigation of the experience of tuberculosis patients for follow up using the internet platform [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 398-403. |
[15] | CAO Xiao-man, LIU Wei, LIU Tao, WANG Chun, GAO Guang-kuo, ZHAI Wen-ting, CHEN Fen, WU Chun-yu. Analysis of the effect of flurbiprofen axetil on postoperative fever in patients with spinal tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 409-412. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||